Dermatology Private Equity Trends

The dermatology sector continues to demonstrate exceptional resilience as one of the most active segments in healthcare private equity. As we move through 2026, several distinct trends are reshaping the landscape for dermatology practice owners evaluating strategic options. Understanding these dynamics is essential for healthcare business owners seeking to maximize transaction value while identifying the right partner for long-term success.

Private Equity Activity Reaches Record Levels

Healthcare private equity delivered record-breaking performance in 2025, with disclosed deal value exceeding $191 billion, surpassing the previous high set in 2021.1 Within this broader healthcare expansion, dermatology maintained its position as one of the most sought-after physician specialties, driven by favorable industry fundamentals and proven scalability.

Transaction volume in dermatology has evolved significantly from the rapid consolidation wave of 2015-2022. While deal counts have stabilized relative to the frothy 2021-2022 period, the quality and sophistication of transactions have increased markedly.2 Recent data suggests dermatology remains highly fragmented, with approximately 10% to 15% of practices backed by private equity, leaving substantial opportunity for continued consolidation.3

Connect with Our Healthcare Team

Current Market Dynamics

Second Bites Drive Market Activity

One of the most significant trends entering 2026 is the maturation of dermatology platforms originally acquired between 2016 and 2020. These groups are now reaching their natural exit timeline, creating a wave of “second bite” recapitalization opportunities.4 Notable recent transactions include platforms such as Forefront Dermatology and DOCS Dermatology Group completing recapitalizations that brought in fresh capital partners to fund continued expansion.

Some platforms that tested the market were unable to secure outcomes compelling enough to proceed with a new buyer, leaving those groups with existing private equity partners.4 This dynamic has limited their ability to pursue large acquisitions, as existing sponsors focus primarily on exit realization rather than deploying additional capital.

Conversely, platforms that successfully completed recent recapitalizations have often become more aggressive in pursuing select acquisitions, as mergers and acquisitions remain their primary growth engine.4 Private equity groups are conducting deeper diligence than in previous cycles, ensuring they partner with practices that align with rigorous standards while prioritizing clinical excellence and physician shareholder longevity.

Regulatory Landscape Creates Geographic Divide

State-level regulatory frameworks are significantly reshaping the geography of dermatology investment. Several states have introduced legislation designed to restrict private equity ownership or management control of medical practices, with Oregon and California among the most notable examples.4 This regulatory evolution is expected to continue, with additional states monitoring early enforcement activity.

Corporate Practice of Medicine Impact

The geographic divide between favorable and restrictive markets is pushing investors toward more selective acquisition strategies. Many private equity groups are avoiding new or expanded dermatology investments in restrictive states, instead concentrating on markets with more advantageous corporate practice of medicine structures.4

In states with stricter requirements, the pool of interested buyers is notably smaller, which limits options for practice owners and reduces competitive tension in sale processes. Despite these challenges, transactions continue to occur, with buyers becoming increasingly sophisticated in how they structure deals in these jurisdictions.

Shift Toward Larger, Infrastructure-Rich Platforms

Buyers are demonstrating a strong preference for medium-to-large practices with professionalized infrastructure already in place. Revenue scale, multi-site density, strong management teams, and integrated ancillary services have become major value drivers.4 Buyers also prioritize shareholder groups with younger, growth-oriented physicians who can remain active in the business long-term and help continue building the platform.

Smaller dermatology groups continue to attract attention, but they must increasingly present a credible path to scale and sustainability, either by joining existing platforms or demonstrating internal growth capability. Investors show less interest in fragmented solo practices and more focus on practices that can integrate directly into scalable operating models.

Key Platform Differentiators

Valuation Trends and EBITDA Multiples

Dermatology practice valuations demonstrate significant variance based on scale, service mix, and operational sophistication. Large dermatology platforms can command 12-15× EBITDA multiples, consistent with 2025 healthcare benchmarks for scaled physician groups.5 Small to mid-sized practices typically trade at 4-9× EBITDA, depending on profitability, payor mix, and ancillary services.

2026 EBITDA Multiple Ranges

Presented for illustration purposes only and not a guarantee of any outcome. Based on works cited and internal banker guidance.

Cosmetic dermatology exposure and in-house ancillaries emerge as top drivers of premium valuations.5 Practices with well-balanced service lines and recurring membership or subscription models can achieve higher multiples than peers without these features.

Revenue Composition Drives Value

Buyers evaluate dermatology practices not solely by top-line revenue but by composition and predictability. A balanced mix of medical and cosmetic services supports margin stability while enabling growth through self-pay and membership-based models.

Medical dermatology provides recurring reimbursement-driven income with typical margins around 25%, while cosmetic dermatology enhances profitability through higher-margin cash-pay procedures at approximately 27% margins.5 Medspa and aesthetics segments can deliver margins exceeding 30%, though these are more growth-sensitive.

Practices that demonstrate strong utilization of advanced procedures, such as Mohs surgery or in-house pathology, show the highest resilience to reimbursement pressure. Conversely, those dependent on commodity medical visits with minimal ancillaries face greater exposure to rate compression and payer policy changes.

Technology Emerges as Value Driver

One notable shift entering 2026 is the increasing emphasis buyers place on technology adoption as a value driver. Nearly 20% of all eHealth transactions completed in 2025 targeted companies with AI-enabled services, including analytics, diagnostics, patient engagement, and revenue cycle management.5 Strategic buyers and private equity firms are increasingly focused on acquiring next-generation technology capability rather than building it internally.

For dermatology, this means practices with integrated AI-assisted diagnostics, robust patient engagement platforms, or established tele-dermatology programs are beginning to distinguish themselves in diligence. While technology alone does not drive multiples, it increasingly serves as a differentiator when buyers compare similarly sized and profiled practices.

Regional Market Trends

Geography remains a consistent differentiator in dermatology transaction outcomes. Buyer activity concentrates most heavily in Sunbelt and suburban metro markets, where demographic tailwinds, including population growth, aging residents, and higher private-pay utilization, support recurring patient volumes.5

Florida, Texas, Arizona, and Georgia continue to experience outsized activity, while suburban regions around Dallas, Phoenix, and Atlanta draw sustained competition among national consolidators. Coastal urban centers remain liquid markets but can face tighter staffing conditions and higher overhead costs, which can slightly compress EBITDA margins.

Investors demonstrate particular interest in practices with satellite offices or de novo growth potential in secondary markets, where acquisition multiples can extend further due to limited local competition.

Active Buyer Landscape

More than 35 sponsor-backed dermatology platforms now operate nationally, with many pursuing a combination of tuck-in acquisitions and de novo expansion.5 Leading consolidators, including Epiphany Dermatology (39 announced deals in the past five years), Pinnacle, Schweiger, Forefront, and DermCare, remain among the most active acquirers.6

Buyer Categories and Targets

Following a modest dip in overall healthcare M&A activity in 2024, deal volume began to recover meaningfully in 2025, with dermatology among the most resilient specialties thanks to recurring patient demand and balanced cash-flow models.5 The 2026 environment shows notable improvement, with interest rates projected to ease and private equity firms redeploying capital across healthcare.

What This Means for Practice Owners

For independent dermatology groups, current market dynamics create both opportunity and complexity. Despite regulatory headwinds in certain regions, dermatology remains one of the most active specialties in healthcare investment. Practices that emphasize growth, clinical excellence, compliance, infrastructure, and scale remain at the forefront of consolidation as investors reengage with the sector.4

Practice owners should carefully evaluate all strategic options, recognizing that private equity represents one potential consideration alongside maintaining 100% physician ownership. The competitive landscape for practice ownership grows more challenging each year, and opportunities available today may look substantially different in the future.

Connect with Our Healthcare Team

Looking Ahead

Despite modest reimbursement headwinds, including a 2.83% reduction in the Medicare conversion factor enacted in 2026, dermatology continues to outperform broader healthcare services on margin durability and transaction multiples.5 Sector expansion is increasingly anchored by aesthetic diversification, tele-dermatology adoption, and recurring medspa models, each of which supports sustained investor confidence.

As consolidation advances, top-performing dermatology practices that combine medical stability with cosmetic growth are positioned to achieve premium valuations. The market depth, scale opportunity, and recurring revenue profile make dermatology one of the most sought-after segments in healthcare mergers and acquisitions.

For dermatology practice owners evaluating strategic decisions, understanding these trends provides essential context to maximize transaction value and identify partners aligned with the long-term vision and practice culture.

Sources